All In Biotech

Drug Trial Radar · NCT04980248

Study of ALXN1850 in Participants With Hypophosphatasia (HPP)

A Phase 1, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1850 in Adults With Hypophosphatasia

Last checked: Nov 20, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

15

Actual

Start

Sep 28, 2021

Primary completion

Aug 24, 2022

Study completion Aug 24, 2022

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, dose-escalating study to assess safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity of ALXN1850 when given intravenous (IV) and subcutaneous (SC) to adults with HPP.

Conditions

  • Hypophosphatasia

Interventions

  • ALXN1850Biological

    ALXN1850 will be administered as an IV infusion and via the SC route.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Time frame: Day 1 up to Day 85

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Columbus, Ohio

  • Research Site

    Nashville, Tennessee

  • Research Site

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.